Skip Navigation
Johns Hopkins Bloomberg School of Public Health

Resources: From pneumoACTION to Now

PneumoACTION ( was launched by the PneumoADIP team at Johns Hopkins Bloomberg School of Public Health and supported by GAVI. The site was a resource of evidence and tools for poliymakers, advocates and other key stakeholders working around the globe to fight childhood pneumonia and pneumococcal disease. As PneumoADIP has become IVAC, we want to preserve and update important resources that can be useful in working toward improved global health policies and their implementation.

IVAC's 2017 Pneumonia and Diarrhea Progress Report

Global Childhood Diseases

Disease Information



View-hub Report (September 2017): current global access to new childhood vaccines

The VIEW-hub report displays data and figures on the introduction status of Haemophilus influenzae type b (Hib) vaccine, pneumococcal conjugate vaccine (PCV), rotavirus vaccine, and inactivated polio vaccine (IPV) both globally and in the 73 Gavi countries. Since March 2016, new additions to the VIEW-hub report are information on countries’ current product and dosing schedule for PCV, rotavirus vaccine, and IPV. The report describes: the number of countries that have introduced each vaccine or plan to in the future; global and Gavi rates of vaccine coverage and access; projected introduction dates for Gavi countries; and historical trends in the rate of global vaccine introduction.

Download the latest View-hub report (September 2017, pdf, 27 pages)
Download the latest View-hub figures (September 2017, slide-deck)

PCV Product Assessment

The availability of multiple pneumococcal vaccines, with overlapping but non-identical characteristics, including formulation, poses decision-making challenges. The purpose of the PCV Product Assessment is to assist countries in making informed decisions around PCV product choice; and to assist Gavi in making informed decisions about PCV product requests (including switches) by countries.

This technical document synthesizes the epidemiologic and biologic evidence regarding pneumococcal conjugate vaccine (PCV) products, and briefly summarizes the programmatic considerations surrounding performance, effectiveness, and impact for current PCV products: 10-valent (PCV10) and 13-valent (PCV13).

Download the PCV Product Assessment  (April 2017, 162 pages)
Download the Brief Summary of the PCV Product Assessment (1 page)

Hib & Pneumococcal Vaccine Use

Vaccines are a critical tool for increasing child survival. Historically, vaccination has proven to be a safe, cost-effective option for dramatically reducing death and disability associated with many childhood diseases, such as pneumonia, measles and polio.

  • Pneumococcal vaccines can protect children from Streptococcus pneumoniae, which is the most common cause of severe pneumonia among children living in the developing world, and can also causes meningitis and sepsis.
  • Hib vaccine is also available to protect children against Haemophilus influenzae type b (Hib), which is another major cause of severe pneumonia, as well as meningitis.

These vaccines have been used successfully primarily in industrialized countries to reduce the burden of child pneumonia.  In recent years, great progress has been made in increasing access to these vaccines for children in developing countries as well. However, much work remains to ensure universal access to these life-saving interventions.

Vaccine Health Impact & Safety

Routine pneumococcal immunization programs in North America and pneumococcal conjugate vaccine (PCV) efficacy studies in Africa demonstrate that multi-valent PCVs have the potential to save millions of children worldwide. Learn more details about vaccine health impact and safety research from North America, The Gambia, South Africa and Rwanda.

Reports & Key Scientific Publications

From global reports to important peer-reviewed literature, see our list of publications by IVAC and partners on pneumococcus, Hib, and rotavirus, and more.



  • Nigeria National Immunisation Coverage Survey (NICS) Briefs 2016-2017 - While Nigeria is committed to the Global Vaccine Action Plan (GVAP), its immunization coverage falls below GVAP goals. These briefs summarize the findings from a national survey of routine immunization coverage in children 12-23 months of age in Nigeria. Results will help identify gaps in immunization coverage and guide immunization programs.
  • Global Roadmap for Child Survival - By tackling just four diseases in the 24 countries with 80% of the world's under-five child deaths, using six available and proven interventions, we can eliminate a majority of the world’s 5.6 million annual, preventable child deaths by 2015.
  • The Cost Effectiveness of Vaccines - Immunization can have a powerful impact on economies from the global level down to the family level, and gives many more children the opportunity to reach their fifth birthday.
  • Breaking Down Barriers to Vaccine Coverage in Nigeria - Highlights of key interventions that can help Nigeria scale up its immunization coverage and save lives.
  • Immunization Coverage Landscape in India (April 2015) - Highlights the disparity in the immunization coverage rates across states in India. 

Country Fact Sheets


Tools & Databases



Detailed descriptions of pneumonia- and vaccine-related terms.